Explore more Johnson & Johnson sites:
Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Clinical Trials
By clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Learn More
By clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Share
Janssen Research & Development
At the height of the outbreak in New York City, Dr. Ed Kuffner took a leave of absence from his job to volunteer at a Brooklyn hospital hard hit by the pandemic. He shares what the experience taught him about his own strengths—and ideas for coping during this unprecedented time.
Johnson & Johnson has an expansive archive of existing drug compounds—and two researchers are leading the charge in combing through this molecular storehouse in pursuit of a possible breakthrough.
It's the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.
Cancer. Alzheimer’s. Even suicide risk. The clues to preventing these and other conditions could be found in our DNA—and these scientists are at the forefront of promising new genetic data research to uncover them.
There are trillions of microorganisms living in your gut—and they might just be the key to helping treat diseases like Crohn's and ulcerative colitis. Meet a researcher who spends her days exploring this microscopic world.
From working to broaden the pool of patients trials have traditionally studied to finding ways for people to participate from the comforts of home, we look at how the company is reinventing clinical trials in truly forward-thinking ways.
Despite being one of the oldest viruses known to infect man, there's been slow progress toward a cure for the disease. But a promising clinical trial, led by Janssen researcher Heather Davis, Ph.D., is sparking hope.
A team of scientists, including those from Janssen and the Lung Cancer Initiative at Johnson & Johnson, found that biomarkers related to the immune system may be able to aid doctors in identifying high-risk lung cancer patients—and treating them—at the earliest stage of the disease.
The company just released its third annual report and leaders from across Janssen share some top takeaways, including a new initiative to include the list price and potential out-of-pocket costs for its most frequently prescribed medicine.
Hundreds of millions of people worldwide have type 2 diabetes. And Chiara Magnone has her sights set on changing what it means to live with the condition, as well as how common complications like chronic kidney disease are treated.
Joe Wolk, who has enjoyed a 20-year tenure at Johnson & Johnson, shares his vision for the company's fiscal future.
For Men's Health Month, school yourself on the latest screenings and treatments for this most common male cancer.
The company just awarded six promising female researchers $150,000 each through its new Scholars Award program—and that's not the only way it's helping women working in the sciences.
Macaya Douoguih volunteered to lead an accelerated clinical program for a new investigational Ebola vaccine at the height of the 2014 epidemic in West Africa. She reflects on her experiences—and why her work must continue today.
The company just released its second-annual report and we're spotlighting the top takeaways for patients, consumers and healthcare professionals, including a look at how Janssen approaches drug pricing.
